CYP2F1

Summary

CYP2F1 (cytochrome P450 family 2 subfamily F member 1, HGNC:2632) is a protein-coding gene on chromosome 19q13.2, encoding Cytochrome P450 2F1 (P24903). May be involved in the metabolism of various pneumotoxicants including naphthalene.

This gene encodes a member of the cytochrome P450 superfamily of enzymes. The cytochrome P450 proteins are monooxygenases which catalyze many reactions involved in drug metabolism and synthesis of cholesterol, steroids and other lipids. This protein localizes to the endoplasmic reticulum and is known to dehydrogenate 3-methylindole, an endogenous toxin derived from the fermentation of tryptophan, as well as xenobiotic substrates such as naphthalene and ethoxycoumarin. This gene is part of a large cluster of cytochrome P450 genes from the CYP2A, CYP2B and CYP2F subfamilies on chromosome 19q.

Source: NCBI Gene 1572 — RefSeq curated summary.

At a glance

• Clinical variants (ClinVar): 105 total
• Druggable target: yes — 1 molecules with ChEMBL bioactivity
• MANE Select transcript: NM_000774

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:2632
Approved symbol	CYP2F1
Name	cytochrome P450 family 2 subfamily F member 1
Location	19q13.2
Locus type	gene with protein product
Status	Approved
Ensembl gene	ENSG00000197446
Ensembl biotype	protein_coding
OMIM	124070
Entrez	1572

Gene structure

Transcript identifiers

Ensembl transcripts: 8 — 4 protein_coding, 2 retained_intron, 1 nonsense_mediated_decay, 1 non_stop_decay

ENST00000331105, ENST00000439903, ENST00000526093, ENST00000531409, ENST00000532164, ENST00000534009, ENST00000903858, ENST00000903859

RefSeq mRNA: 1 — MANE Select: NM_000774 NM_000774

CCDS: CCDS12572

Canonical transcript exons

ENST00000331105 — 10 exons

Exon	Start	End
ENSE00000708319	41122822	41122963
ENSE00002148498	41114432	41114492
ENSE00003089868	41116178	41116359
ENSE00003527294	41127901	41128381
ENSE00003531470	41121957	41122133
ENSE00003611106	41116455	41116617
ENSE00003626351	41125493	41125634
ENSE00003647585	41120347	41120496
ENSE00003662288	41124719	41124906
ENSE00003681440	41121458	41121618

Expression profiles

Bgee: expression breadth broad, 98 present calls, max score 96.88.

FANTOM5 (CAGE): breadth tissue_specific, TPM avg 0.0528 / max 21.9276, expressed in 15 samples.

FANTOM5 promoters (1 alternative TSS)

Promoter ID	TPM avg	Samples expressed
175922	0.0528	15

Top tissues by expression

114 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
olfactory segment of nasal mucosa	UBERON:0005386	96.88	gold quality
primordial germ cell in gonad	CL:0000670 ∩ UBERON:0000991	87.97	gold quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	87.41	gold quality
lower esophagus mucosa	UBERON:0035834	72.92	gold quality
stromal cell of endometrium	CL:0002255	63.90	gold quality
right lung	UBERON:0002167	60.58	gold quality
testis	UBERON:0000473	57.96	gold quality
right testis	UBERON:0004534	57.29	gold quality
left testis	UBERON:0004533	57.00	gold quality
esophagus mucosa	UBERON:0002469	56.66	gold quality
colonic epithelium	UBERON:0000397	55.82	gold quality
bone marrow cell	CL:0002092	54.84	gold quality
sural nerve	UBERON:0015488	54.36	gold quality
minor salivary gland	UBERON:0001830	54.35	gold quality
bone marrow	UBERON:0002371	54.23	silver quality
lung	UBERON:0002048	54.00	gold quality
tonsil	UBERON:0002372	53.23	gold quality
saliva-secreting gland	UBERON:0001044	52.10	gold quality
upper lobe of left lung	UBERON:0008952	51.22	gold quality
vagina	UBERON:0000996	51.13	gold quality
granulocyte	CL:0000094	50.30	silver quality
esophagus	UBERON:0001043	47.81	gold quality
leukocyte	CL:0000738	47.55	gold quality
blood	UBERON:0000178	47.08	gold quality
monocyte	CL:0000576	46.91	gold quality
uterine cervix	UBERON:0000002	44.82	gold quality
right adrenal gland cortex	UBERON:0035827	44.68	gold quality
liver	UBERON:0002107	44.58	silver quality
ectocervix	UBERON:0012249	43.38	gold quality
fallopian tube	UBERON:0003889	42.19	gold quality

Single-cell (SCXA)

Detected in 2 experiment(s), a significant marker in 2.

Experiment	Marker?	Max mean expression
E-CURD-114	yes	48.80
E-ANND-3	no	0.00

Regulation

Is transcription factor: no

Upstream regulators (CollecTRI, top): SP1, SP3, TFCP2

miRNA regulators (miRDB)

11 targeting CYP2F1, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-5680	99.91	69.83	3421
HSA-MIR-12129	99.72	67.45	1311
HSA-MIR-4463	98.56	66.05	1071
HSA-MIR-3179	98.22	65.90	1445
HSA-MIR-3173-5P	97.35	65.82	1282
HSA-MIR-6799-3P	97.35	65.60	1302
HSA-MIR-4800-5P	97.22	65.91	324
HSA-MIR-6515-5P	97.08	65.48	1219
HSA-MIR-134-3P	96.83	66.22	1001
HSA-MIR-5002-3P	95.75	67.04	542
HSA-MIR-5090	93.28	60.86	94

Literature-anchored findings (GeneRIF, showing 7)

• a novel LSF(lung-specific factor) and its consensus sequence that may control tissue-specific expression of CYP2F1. (PMID:12598524)
• A lot of genetic polymorphism of CYP2F1 gene is found in Guangdong population of China, however, no single genetic polymorphism associated with the individual susceptibility to nasopharyngeal carcinoma can be identified. (PMID:16883522)
• 24 novel mutations distributed in the promoter region of the gene, as well as in the coding regions and their flanking intronic sequences;the CYP2F1 genetic polymorphism has no implications in the pathogenesis of lung cancer (PMID:17327131)
• Association analysis of CYP2F1 gene insertion variant with chronic obstructive pulmonary disease have shown high frequency (87.5%) of normal allele in Tatars patients with very severe stage and manifestation of chronic obstructive pulmonary disease. (PMID:20198857)
• Patients with occupational chronic bronchitis and healthy workers significantly differed from each other in the frequency distribution of the genotypes ofthe CYP2F1 (rs11399890, c.14_15insC (PMID:22232929)
• Tissue distribution of transgenic mRNA expression agrees well with the known respiratory tract-selective expression of CYP2A13 and CYP2F1 and hepatic expression of CYP2B6 in humans. (PMID:22397853)
• Polymorphism of cytochrome P-4502E1 (CYP2E1) genotype is an important criterion for the development of hepatotoxicity before and during TB treatment. (PMID:29171455)

Cross-species orthologs

2 orthologs

Organism	Symbol	Gene ID
mus_musculus	Cyp2f2	ENSMUSG00000052974
rattus_norvegicus	Cyp2f4	ENSRNOG00000032805

Paralogs (15): CYP2W1 (ENSG00000073067), CYP2D6 (ENSG00000100197), CYP2C18 (ENSG00000108242), CYP2E1 (ENSG00000130649), CYP2J2 (ENSG00000134716), CYP2C9 (ENSG00000138109), CYP2C8 (ENSG00000138115), CYP2U1 (ENSG00000155016), CYP2C19 (ENSG00000165841), CYP2S1 (ENSG00000167600), CYP2R1 (ENSG00000186104), CYP2B6 (ENSG00000197408), CYP2A13 (ENSG00000197838), CYP2A7 (ENSG00000198077), CYP2A6 (ENSG00000255974)

Protein

Protein identifiers

Cytochrome P450 2F1 — P24903 (reviewed: P24903)

Alternative names: CYPIIF1

All UniProt accessions (3): P24903, A0A075B795, H0YGI9

UniProt curated annotations — full annotation on UniProt →

Function. May be involved in the metabolism of various pneumotoxicants including naphthalene. Is able to dealkylate ethoxycoumarin, propoxycoumarin, and pentoxyresorufin but possesses no activity toward ethoxyresorufin and only trace dearylation activity toward benzyloxyresorufin. Bioactivates 3-methylindole (3MI) by dehydrogenation to the putative electrophile 3-methylene-indolenine.

Subcellular location. Endoplasmic reticulum membrane. Microsome membrane.

Tissue specificity. Expressed in lung. Rarely detected in liver and placenta.

Polymorphism. Eight non disease-associated alleles are known: CYP2F11, CYP2F12A, CYP2F12B, CYP2F13, CYP2F14, CYP2F15A, CYP2F15B and CYP2F16. The sequence shown corresponds to allele CYP2F1*1.

Similarity. Belongs to the cytochrome P450 family.

Isoforms (2)

UniProt ID	Names	Canonical?
P24903-1	1	yes
P24903-2	2

RefSeq proteins (1): NP_000765* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR001128	Cyt_P450	Family
IPR002401	Cyt_P450_E_grp-I	Family
IPR017972	Cyt_P450_CS	Conserved_site
IPR020469	Cyt_P450_CYP2_fam	Family
IPR036396	Cyt_P450_sf	Homologous_superfamily
IPR050182	Cytochrome_P450_fam2	Family

Pfam: PF00067

Catalyzed reactions (Rhea), 1 shown:

• an organic molecule + reduced [NADPH–hemoprotein reductase] + O2 = an alcohol + oxidized [NADPH–hemoprotein reductase] + H2O + H(+) (RHEA:17149)

UniProt features (14 total): sequence variant 6, sequence conflict 4, splice variant 2, chain 1, binding site 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-P24903-F1	93.38	0.86

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Ligand- & substrate-binding residues (1): 436 (axial binding residue)

Function

Pathways and Gene Ontology

Reactome pathways

3 pathways

ID	Pathway
R-HSA-211935	Fatty acids
R-HSA-211981	Xenobiotics
R-HSA-211999	CYP2E1 reactions

MSigDB gene sets: 135 (showing top): GSE45365_CTRL_VS_MCMV_INFECTION_NK_CELL_UP, REACTOME_BIOLOGICAL_OXIDATIONS, GOMF_OXIDOREDUCTASE_ACTIVITY_ACTING_ON_PAIRED_DONORS_WITH_INCORPORATION_OR_REDUCTION_OF_MOLECULAR_OXYGEN, YAO_HOXA10_TARGETS_VIA_PROGESTERONE_UP, GRAESSMANN_APOPTOSIS_BY_DOXORUBICIN_UP, GRAESSMANN_RESPONSE_TO_MC_AND_DOXORUBICIN_UP, GOBP_LONG_CHAIN_FATTY_ACID_METABOLIC_PROCESS, GOBP_MONOCARBOXYLIC_ACID_METABOLIC_PROCESS, LEE_LIVER_CANCER_CIPROFIBRATE_DN, CAGCTG_AP4_Q5, GCM_PRKCG, SHETH_LIVER_CANCER_VS_TXNIP_LOSS_PAM4, GCM_FCGR2B, SCHAEFFER_PROSTATE_DEVELOPMENT_6HR_DN, SCHAEFFER_PROSTATE_DEVELOPMENT_48HR_UP

GO Biological Process (4): xenobiotic metabolic process (GO:0006805), response to toxic substance (GO:0009636), epoxygenase P450 pathway (GO:0019373), naphthalene catabolic process (GO:1901170)

GO Molecular Function (9): monooxygenase activity (GO:0004497), iron ion binding (GO:0005506), arachidonate epoxygenase activity (GO:0008392), oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen (GO:0016712), oxygen binding (GO:0019825), heme binding (GO:0020037), oxidoreductase activity (GO:0016491), oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen (GO:0016705), metal ion binding (GO:0046872)

GO Cellular Component (5): cytoplasm (GO:0005737), endoplasmic reticulum membrane (GO:0005789), intracellular membrane-bounded organelle (GO:0043231), endoplasmic reticulum (GO:0005783), membrane (GO:0016020)

Reactome top-level categories

Rollup of top-2 pathways:

Category	Pathways
Cytochrome P450 - arranged by substrate type	2
Xenobiotics	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
oxidoreductase activity	2
intracellular anatomical structure	2
cellular anatomical structure	2
metabolic process	1
cellular response to xenobiotic stimulus	1
response to chemical	1
arachidonate metabolic process	1
hydrocarbon catabolic process	1
transition metal ion binding	1
arachidonate monooxygenase activity	1
monooxygenase activity	1
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen	1
small molecule binding	1
tetrapyrrole binding	1
catalytic activity	1
cation binding	1
organelle membrane	1
nuclear outer membrane-endoplasmic reticulum membrane network	1
endoplasmic reticulum subcompartment	1
membrane-bounded organelle	1
intracellular organelle	1
cytoplasm	1
endomembrane system	1
intracellular membrane-bounded organelle	1

Protein interactions and networks

STRING

1232 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
CYP2F1	PPIG	Q13427	800
CYP2F1	ERP29	P30040	763
CYP2F1	APOC2	P02655	683
CYP2F1	PIGQ	Q9BRB3	580
CYP2F1	SUSD1	Q6UWL2	486
CYP2F1	PEPD	P12955	477
CYP2F1	CAPN9	O14815	455
CYP2F1	SEPSECS	Q9HD40	445
CYP2F1	ABHD8	Q96I13	443
CYP2F1	CYP4F11	Q9HBI6	433
CYP2F1	CHFR	Q96EP1	402
CYP2F1	CYP26B1	Q9NR63	396
CYP2F1	OR2T5	Q6IEZ7	392
CYP2F1	CYP4F22	Q6NT55	377
CYP2F1	DRC12	Q494R4	369

IntAct

2 interactions, top by confidence:

A	B	Type	Score
Mecom	ESYT2	psi-mi:“MI:0914”(association)	0.350

BioGRID (1): HIST1H2BD (Cross-Linking-MS (XL-MS))

ESM2 similar proteins: E9Q5K4, O18809, O35293, O55071, O93297, O93299, P00176, P00178, P00179, P00180, P00181, P04167, P05178, P08683, P10610, P10632, P11371, P11372, P11509, P11712, P12789, P12790, P12791, P15123, P15392, P17666, P20812, P20813, P20852, P20853, P24460, P24461, P24470, P24903, P33260, P33261, P33262, P33263, P33264, P33267

Diamond homologs: A0A087X1C5, E9Q5K4, F1Q8C3, O18809, O18992, O35293, O46658, O54749, O54750, O55071, O62671, O93297, P00176, P00178, P00179, P00180, P00181, P00182, P04167, P05178, P05179, P05180, P05181, P08682, P08683, P10610, P10632, P10633, P10634, P10635, P11371, P11712, P11714, P12789, P12790, P12791, P12938, P12939, P15123, P17666

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

105 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	84
Likely benign	5
Benign	8

Top pathogenic / likely-pathogenic (0)

SpliceAI

1248 predictions. Top by Δscore:

Variant	Effect	Δscore
19:41116453:A:AG	acceptor_gain	1.0000
19:41116454:G:GG	acceptor_gain	1.0000
19:41116454:GCT:G	acceptor_gain	1.0000
19:41116454:GCTGA:G	acceptor_gain	1.0000
19:41120342:CCCA:C	acceptor_loss	1.0000
19:41120343:CCAG:C	acceptor_loss	1.0000
19:41120344:CAG:C	acceptor_loss	1.0000
19:41120345:A:AG	acceptor_gain	1.0000
19:41120345:AGG:A	acceptor_loss	1.0000
19:41120346:G:GG	acceptor_gain	1.0000
19:41120346:GGC:G	acceptor_gain	1.0000
19:41120494:AAGGT:A	donor_loss	1.0000
19:41120496:GGTC:G	donor_loss	1.0000
19:41120497:GTCAG:G	donor_loss	1.0000
19:41120498:T:G	donor_loss	1.0000
19:41121628:C:G	donor_gain	1.0000
19:41121947:T:TA	acceptor_gain	1.0000
19:41121953:CCAGT:C	acceptor_loss	1.0000
19:41121955:A:AG	acceptor_gain	1.0000
19:41121955:A:C	acceptor_loss	1.0000
19:41121955:AGTT:A	acceptor_gain	1.0000
19:41121956:G:GG	acceptor_gain	1.0000
19:41121956:GTT:G	acceptor_gain	1.0000
19:41121956:GTTG:G	acceptor_gain	1.0000
19:41121956:GTTGT:G	acceptor_gain	1.0000
19:41122130:AGAG:A	donor_loss	1.0000
19:41122131:GAG:G	donor_gain	1.0000
19:41122134:G:GA	donor_loss	1.0000
19:41122135:T:G	donor_loss	1.0000
19:41122820:A:AG	acceptor_gain	1.0000

AlphaMissense

3222 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
19:41125625:T:C	F429L	0.984
19:41125627:C:A	F429L	0.984
19:41125627:C:G	F429L	0.984
19:41125544:T:C	F402L	0.982
19:41125546:C:A	F402L	0.982
19:41125546:C:G	F402L	0.982
19:41125577:T:C	F413L	0.982
19:41125579:T:A	F413L	0.982
19:41125579:T:G	F413L	0.982
19:41125562:T:C	F408L	0.976
19:41125564:C:A	F408L	0.976
19:41125564:C:G	F408L	0.976
19:41125563:T:C	F408S	0.962
19:41127945:T:C	F447L	0.961
19:41127947:T:A	F447L	0.961
19:41127947:T:G	F447L	0.961
19:41124805:G:C	A351P	0.958
19:41116566:T:C	F95L	0.953
19:41116568:T:A	F95L	0.953
19:41116568:T:G	F95L	0.953
19:41127975:T:C	F457L	0.950
19:41127977:T:A	F457L	0.950
19:41127977:T:G	F457L	0.950
19:41128056:T:C	F484L	0.941
19:41128058:C:A	F484L	0.941
19:41128058:C:G	F484L	0.941
19:41124818:A:T	E355V	0.933
19:41124819:G:C	E355D	0.927
19:41124819:G:T	E355D	0.927
19:41124826:C:A	R358S	0.927

dbSNP variants (sampled 300 via entrez): RS1000247990 (19:41118203 C>A), RS1000401024 (19:41123814 G>A,T), RS1000407115 (19:41119878 G>A,T), RS1000629390 (19:41124178 C>G), RS1001138552 (19:41117135 T>A), RS1001753602 (19:41118743 C>A,T), RS1002060730 (19:41126030 G>A,T), RS1002171242 (19:41115905 A>T), RS1002920547 (19:41112875 C>G,T), RS1003112412 (19:41113111 G>T), RS1003114892 (19:41117880 C>T), RS1003175631 (19:41117182 G>A), RS1003280100 (19:41126944 A>G,T), RS1003689247 (19:41127226 T>A,C), RS1004292236 (19:41116629 C>T)

Disease associations

OMIM: gene MIM:124070 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

0 associations (top):

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (1): CHEMBL4523986 (PROTEIN FAMILY)

Molecules with ChEMBL bioactivity

1 molecules (phase ≥1), by development phase (incl. off-target/promiscuous compounds). Patent mentions across the top 20 by phase: 15,540 (via chembl_molecule»patent_compound — counts attach to the compound, not the gene–compound relationship, so off-target/promiscuous molecules can dominate).

Molecule	Name	Phase	Patents
CHEMBL477772	PAZOPANIB	4	15,540

PharmGKB: 1 entry (VIP=true, CPIC=false)

PharmGKB clinical annotations

1 annotations.

Variant	Type	Level	Drugs	Phenotypes
rs305968	Toxicity	3	imatinib	Gastrointestinal Stromal Tumors

PharmGKB variants

1 variants.

Variant	Genes	Level	Score	#Clin annots	Drugs
rs305968	CYP2F1	3	1.50	1	imatinib

GtoPdb / IUPHAR curated pharmacology

(IUPHAR/BPS Guide to Pharmacology — expert-curated)

Target class: enzyme — CYP2 family: drug metabolising subset

ChEMBL bioactivities

16 potent at pChembl≥5 of 17 total, top 16 by pChembl (potency: 10 = 0.1 nM, 6 = 1 µM).

pChembl	Type	Value	Unit	Molecule
6.60	IC50	251.2	nM	CHEMBL601428
6.16	IC50	700	nM	CHEMBL3330409
6.05	IC50	900	nM	CHEMBL3330410
5.96	IC50	1100	nM	CHEMBL2130955
5.72	IC50	1900	nM	CHEMBL2130955
5.60	IC50	2500	nM	CHEMBL5612347
5.55	IC50	2800	nM	CHEMBL2130955
5.43	IC50	3700	nM	CHEMBL5406721
5.43	IC50	3700	nM	CHEMBL46909
5.42	IC50	3800	nM	CHEMBL5418617
5.41	IC50	3900	nM	CHEMBL5429178
5.31	IC50	4900	nM	CHEMBL2130955
5.23	IC50	5900	nM	CHEMBL5406218
5.22	IC50	6053	nM	CHEMBL65590
5.10	IC50	7900	nM	PAZOPANIB
5.00	IC50	1e+04	nM	CHEMBL5395150

PubChem BioAssay actives

18 with measured affinity, of 466 total; 15 most potent distinct compounds. Largely complementary to BindingDB; screening values are coarse (µM, 4 dp), so sub-nM hits tie at the floor.

Compound	Assay	Type	Value	Unit
8-imidazol-1-yl-5,6,7,8-tetrahydroquinoline	2022035: Inhibition of CYP450 (unknown origin)	ic50	0.0335	uM
N-(4-chlorophenyl)-5-ethyl-N-methyl-3-phenyl-1,2-oxazole-4-carboxamide	2108148: Inhibition of CYP450 (unknown origin)	ic50	0.2512	uM
2-(dimethylamino)-2-(2-ethylphenyl)-N-[3-(3-sulfamoylphenyl)-1H-indazol-5-yl]acetamide	2119433: Inhibition of CYP450 (unknown origin)	ic50	0.7000	uM
2-pyrrolidin-1-yl-N-[3-(3-sulfamoylphenyl)-1H-indazol-5-yl]-2-thiophen-3-ylacetamide	2119433: Inhibition of CYP450 (unknown origin)	ic50	0.9000	uM
2-[4-(trifluoromethyl)phenyl]chromen-4-one	1860369: Inhibition of CYP450 in human HCT-116 cells assessed as 20-HETE formation in presence of arachidonic acid incubated for 15 mins by multi-enzyme assay based LC-MS/MS analysis	ic50	1.1000	uM
4-N-[(1S)-1,2,3,4-tetrahydronaphthalen-1-yl]-4-N-[[(7R)-5,6,7,8-tetrahydro-1,6-naphthyridin-7-yl]methyl]cyclohexane-1,4-diamine	2124397: Inhibition of CYP450 (unknown origin)	ic50	2.5000	uM
1-[3-(2,4-dimethoxyphenyl)phenyl]-2,4-dimethoxybenzene	1973305: Inhibition of CYP450 in pooled human liver microsomes in presence of NADPH measured every 3 mins for 120 mins by fluorescence based analysis	ic50	3.7000	uM
1-[(E)-2-(2,4-dimethoxyphenyl)ethenyl]-3,5-dimethoxybenzene	1973305: Inhibition of CYP450 in pooled human liver microsomes in presence of NADPH measured every 3 mins for 120 mins by fluorescence based analysis	ic50	3.7000	uM
2,4-bis(3,5-dimethoxyphenyl)pyrimidine	1973305: Inhibition of CYP450 in pooled human liver microsomes in presence of NADPH measured every 3 mins for 120 mins by fluorescence based analysis	ic50	3.8000	uM
2,5-bis(3,5-dimethoxyphenyl)thiophene	1973305: Inhibition of CYP450 in pooled human liver microsomes in presence of NADPH measured every 3 mins for 120 mins by fluorescence based analysis	ic50	3.9000	uM
4-[2-(2,4-dimethoxyphenyl)-1,3-thiazol-4-yl]phenol	1973305: Inhibition of CYP450 in pooled human liver microsomes in presence of NADPH measured every 3 mins for 120 mins by fluorescence based analysis	ic50	5.9000	uM
1-pyridin-4-yl-1a,2,3,7b-tetrahydro-1H-cyclopropa[a]naphthalen-4-ol	2022025: Inhibition of CYP450 in human liver microsomes	ic50	6.0534	uM
(5R)-3-[1-(1H-indol-2-ylmethyl)piperidin-4-yl]-5-(6-methoxyquinolin-4-yl)-1,3-oxazolidin-2-one	306257: Inhibition of CYP450	ic50	7.9433	uM
3-[1-[(3,4-dimethylphenyl)methyl]piperidin-4-yl]-5-(6-methoxyquinolin-4-yl)-1,3-oxazolidin-2-one	306257: Inhibition of CYP450	ic50	10.0000	uM
1-[3-(3,5-dimethoxyphenyl)phenyl]-3,5-dimethoxybenzene	1973305: Inhibition of CYP450 in pooled human liver microsomes in presence of NADPH measured every 3 mins for 120 mins by fluorescence based analysis	ic50	10.0000	uM

CTD chemical–gene interactions

25 total (human), top 25 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Skatole	increases metabolic processing, increases chemical synthesis, decreases reaction, increases expression, affects binding (+2 more)	2
alpha-naphthoflavone	affects binding, decreases activity, decreases reaction, increases expression	1
sodium arsenite	increases abundance, increases expression	1
naphthalene	affects cotreatment, affects reaction, increases metabolic processing	1
1-aminobenzotriazole	decreases reaction, increases expression	1
cylindrospermopsin	decreases expression	1
3-methyleneindolenine	increases chemical synthesis, increases metabolic processing	1
2-palmitoylglycerol	increases expression	1
Gefitinib	decreases expression	1
Arsenic	increases abundance, increases expression	1
Benzene	increases hydroxylation	1
Benzo(a)pyrene	increases methylation	1
Cycloheximide	decreases reaction, increases expression	1
Dactinomycin	increases expression, decreases reaction	1
Diethylhexyl Phthalate	decreases expression	1
Estradiol	decreases expression, affects cotreatment, increases expression	1
Fluorouracil	affects expression	1
Parathion	affects cotreatment, increases expression	1
Phenobarbital	increases expression	1
Rifampin	decreases expression	1
Tobacco Smoke Pollution	decreases expression	1
Toluene	increases expression	1
Zinc	increases expression	1
8-Bromo Cyclic Adenosine Monophosphate	decreases expression	1
Asbestos, Serpentine	increases methylation	1

ChEMBL screening assays

183 unique, capped per target: 181 admet, 2 binding

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL2060324	ADMET	Inhibition of CYP450	Rapid identification of ETP-46992, orally bioavailable PI3K inhibitor, selective versus mTOR. — Bioorg Med Chem Lett
CHEMBL4614611	Binding	Drug metabolism in human liver microsomes assessed as Cytochrome P450-mediated formation of 12-OHNVP by measuring Kcat/Km ratio in presence of NADPH regenerating reagents by uHPLC-MS/MS analysis	Twelfth-Position Deuteration of Nevirapine Reduces 12-Hydroxy-Nevirapine Formation and Nevirapine-Induced Hepatocyte Death. — J Med Chem

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.